Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC.ATOS · Entity 7556 | Director | May 12, 2026 | May 14, 2026 |
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Director | September 02, 2026 | September 04, 2026 |
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Chief Financial Officer | June 15, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATOSSA THERAPEUTICS, INC.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2026-05-12 transaction · row 1
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 10,000 · Balance 10,000 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026.
Actinium Pharmaceuticals, Inc.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,116 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Grant · Acquired 62,800 · Balance 63,116 F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2036-09-02 | Direct | 94,200 |
Reported balance
After 2026-09-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-02 · Grant · Acquired 94,200 · Balance 94,200 F2: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant.
F2: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant.
BioXcel Therapeutics, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,335 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Exercise / conversion · Acquired 35 · Balance 26,335 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 212 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Exercise / conversion · Disposed 35 · Balance 212 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 4, 2026 21:00 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 94,200 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001213900-26-097740 · ownership.xml · derivative · entry 2 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,200 Underlying: Common Stock · 94,200 shares Expires 2036-09-02 F2 · derivative.exercise_date: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 21:00 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantCommon Stock | 62,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-097740 · ownership.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,116 F1 · shares: Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-075301 · tm2618120-3_4seq1.xml · derivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212 Underlying: Common Stock · 35 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 35 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-075301 · tm2618120-3_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 6,845 | $1.09 | $7,426.83 |
DisclosureSEC source: 0001104659-26-065838 · tm2615413-2_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,300 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2026 solely to cover taxes due in connection with the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.07 to $1.105. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 12, 2026 Filed May 14, 2026 22:32 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-224521 · ownership.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026. Read SEC document |
| May 04, 2026 Filed May 22, 2026 23:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-065838 · tm2615413-2_4seq1.xml · derivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the "Vesting Commencement Date"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the "Vesting Commencement Date"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| May 04, 2026 Filed May 22, 2026 23:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-065838 · tm2615413-2_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 01, 2026 Filed May 7, 2026 23:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-057366 · tm2613630-3_4seq1.xml · derivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date. F2 · derivative.expiration_date: On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date. Read SEC document |
| May 01, 2026 Filed May 7, 2026 23:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-057366 · tm2613630-3_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 00:04 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-028721 · tm268882-3_4seq1.xml · derivative · entry 4 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247 Underlying: Common Stock · 35 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 00:04 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 35 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-028721 · tm268882-3_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 00:04 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-028721 · tm268882-3_4seq1.xml · derivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97 Underlying: Common Stock · 33 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 00:04 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 33 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-028721 · tm268882-3_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 01, 2026 Filed Jan 6, 2026 01:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-000837 · tm261931-3_4seq1.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,282 Underlying: Common Stock · 70,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the "Vesting Commencement Date"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the "Vesting Commencement Date"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 01:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-121303 · tm2533410-3_4seq1.xml · derivative · entry 4 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282 Underlying: Common Stock · 35 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 01:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 35 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-121303 · tm2533410-3_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 14, 2025 Filed Dec 16, 2025 01:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-121303 · tm2533410-3_4seq1.xml · derivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130 Underlying: Common Stock · 33 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 14, 2025 Filed Dec 16, 2025 01:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 33 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-121303 · tm2533410-3_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 23:04 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-090517 · tm2526247-3_4seq1.xml · derivative · entry 4 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317 Underlying: Common Stock · 35 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 23:04 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 35 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-090517 · tm2526247-3_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 14, 2025 Filed Sep 16, 2025 23:04 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-090517 · tm2526247-3_4seq1.xml · derivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163 Underlying: Common Stock · 33 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| September 14, 2025 Filed Sep 16, 2025 23:04 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 33 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-090517 · tm2526247-3_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-074372 · tm2522669-4_4seq1.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date. F2 · derivative.expiration_date: On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date. Read SEC document |
| July 22, 2025 Filed Jul 23, 2025 00:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 625 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-069701 · tm2521458-2_4seq1.xml · derivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On July 22, 2024, the Reporting Person was granted 625 RSUs, which vested as to 100% of the total number of RSUs on the first anniversary of the grant date. F3 · derivative.expiration_date: On July 22, 2024, the Reporting Person was granted 625 RSUs, which vested as to 100% of the total number of RSUs on the first anniversary of the grant date. Read SEC document |
| July 22, 2025 Filed Jul 23, 2025 00:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-069701 · tm2521458-2_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 22, 2025 Filed Jul 23, 2025 00:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantCommon Stock | 4,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-069701 · tm2521458-2_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,816 F1 · price: The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through July 22, 2025 (the "PSUs"). On July 22, 2025, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 4,375 PSUs had been satisfied and 4,375 shares of common stock became issuable to the Reporting Person on July 22, 2025. Read SEC document |
| June 15, 2025 Filed Jun 16, 2025 23:03 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-059982 · tm2518140-4_4seq1.xml · derivative · entry 4 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352 Underlying: Common Stock · 35 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 15, 2025 Filed Jun 16, 2025 23:03 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 35 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-059982 · tm2518140-4_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 14, 2025 Filed Jun 16, 2025 23:03 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-059982 · tm2518140-4_4seq1.xml · derivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196 Underlying: Common Stock · 33 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 14, 2025 Filed Jun 16, 2025 23:03 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 33 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-059982 · tm2518140-4_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:05 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000950170-25-073513 · ownership.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-05-15 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over 12 months following May 15, 2025, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued on May 15, 2025 with an exercise price of $0.99, representing the closing stock price on May 15, 2025. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:22 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,311 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-25-028232 · ownership.xml · derivative · entry 8 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,311 shares Expires 2033-12-28 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · balance_after: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:22 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 72,156 | $0.00 Strike: $4.96 | $0.00 |
DisclosureSEC source: 0001213900-25-028232 · ownership.xml · derivative · entry 7 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,156 shares Expires 2032-07-01 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · balance_after: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:22 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,351 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001213900-25-028232 · ownership.xml · derivative · entry 6 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,351 shares Expires 2031-09-01 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · balance_after: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:22 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,333 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001213900-25-028232 · ownership.xml · derivative · entry 5 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,333 shares Expires 2030-08-12 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · balance_after: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:22 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,333 | $0.00 Strike: $6.96 | $0.00 |
DisclosureSEC source: 0001213900-25-028232 · ownership.xml · derivative · entry 4 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires 2029-07-12 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · balance_after: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:22 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $23.49 | $0.00 |
DisclosureSEC source: 0001213900-25-028232 · ownership.xml · derivative · entry 3 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2028-07-13 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · balance_after: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:22 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $41.70 | $0.00 |
DisclosureSEC source: 0001213900-25-028232 · ownership.xml · derivative · entry 2 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2027-03-14 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · balance_after: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:22 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $59.70 | $0.00 |
DisclosureSEC source: 0001213900-25-028232 · ownership.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2026-04-15 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · balance_after: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 15, 2025 Filed Mar 17, 2025 22:38 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 34 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-024534 · tm259558-4_4seq1.xml · derivative · entry 4 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387 Underlying: Common Stock · 34 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 15, 2025 Filed Mar 17, 2025 22:38 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 34 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-024534 · tm259558-4_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 22:38 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 31 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-024534 · tm259558-4_4seq1.xml · derivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229 Underlying: Common Stock · 31 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 22:38 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 31 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-024534 · tm259558-4_4seq1.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 07, 2025 Filed Jan 11, 2025 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (right to buy) · Derivative | 270,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001104659-25-002689 · tm252892-3_4seq1.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2035-01-07 F1 · derivative.exercise_date: On January 7, 2025, the Reporting Person was granted an option to purchase 270,000 shares of common stock, which vests in twelve equal monthly installments over a twelve-month period following the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 23:06 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 372 | $0.36 | $133.18 |
DisclosureSEC source: 0001104659-24-129461 · tm2431371-3_4seq1.xml · nonDerivative · entry 4 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,932 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 23:06 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 205 | $0.36 | $73.80 |
DisclosureSEC source: 0001104659-24-129461 · tm2431371-3_4seq1.xml · nonDerivative · entry 3 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,157 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 23:06 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 562 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-129461 · tm2431371-3_4seq1.xml · derivative · entry 6 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,064 Underlying: Common Stock · 562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 23:06 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 562 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-129461 · tm2431371-3_4seq1.xml · nonDerivative · entry 2 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 14, 2024 Filed Dec 17, 2024 23:06 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 521 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-129461 · tm2431371-3_4seq1.xml · derivative · entry 5 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,606 Underlying: Common Stock · 521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.